Analysts Raise Edwards Lifesciences Price Targets; Truist Upgrades to Buy

Truist Securities upgraded Edwards Lifesciences to Buy from Hold and raised its price target to $113. JPMorgan maintained Overweight and lifted its target to $120; other firms also raised targets.